/HIND
HIND Stock - Vyome Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$3.68-5.08%
$0.20 (-5.08%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+307.6%upside
Target: $15.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HIND
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.64 – $3.72
TARGET (TP)$15.00
STOP LOSS$3.39
RISK/REWARD1:39.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.22
52W High$519.00
52W Low$3.57
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.01M | $8.68M | $11.24M | $13.60M | $11.30M |
| Gross Profit | $5.06M | $5.55M | $6.80M | $8.35M | $6.26M |
| Gross Margin | 63.2% | 63.9% | 60.5% | 61.4% | 55.4% |
| Operating Income | $-7,728,000 | $-14,639,000 | $-27,078,000 | $-57,882,000 | $-12,457,000 |
| Net Income | $-7,130,000 | $-11,387,000 | $-46,214,000 | $-63,146,000 | $-21,630,000 |
| Net Margin | -89.1% | -131.2% | -411.2% | -464.3% | -191.4% |
| EPS | $-345.74 | $-2771.94 | $-157897.00 | $-419004.00 | $-503023.26 |
Company Overview
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HINDBeat Rate
38%
Last 16 quarters
Avg Surprise
-3526.5%
EPS vs Estimate
Beats / Misses
6/10
Last 12 quarters
Latest EPS
$-3.12
Q4 2025
EPS Surprise History
Q1 24
+38.9%
$-0.11vs$-0.18
Q2 24
-3168.8%
$-5.23vs$-0.16
Q3 24
+49.9%
$-3.49vs$-6.96
Q4 24
+46.4%
$-3.11vs$-5.80
Q2 25
+53.4%
$-47.25vs$-101.50
Q2 25
No data
Q3 25
No data
Q4 25
-2736.4%
$-3.12vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 18, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.11 | $-3.12 | -2736.4% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | — | $-2.25 | — | — |
Q2 2025 | May 20, 2025 | — | $18.98 | — | — |
Q2 2025 | Apr 4, 2025 | $-101.50 | $-47.25 | +53.4% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-5.80 | $-3.11 | +46.4% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-6.96 | $-3.49 | +49.9% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.16 | $-5.23 | -3168.8% | ✗ MISS |
Q1 2024 | Feb 23, 2024 | $-0.18 | $-0.11 | +38.9% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-1.20 | $-59.30 | -4841.7% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-1.79 | $-62.79 | -3407.8% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-4.21 | $-90.70 | -2054.4% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-10.00 | $-8.59 | +14.1% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-17.75 | $-552.33 | -3011.7% | ✗ MISS |
Q3 2022 | Aug 19, 2022 | $-18.00 | $-1191.86 | -6521.4% | ✗ MISS |
Q2 2022 | May 23, 2022 | $-17.00 | $-1104.65 | -6397.9% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-8.50 | $145.35 | +1810.0% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $-7.50 | $-901.16 | -11915.5% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | — | $-436.05 | — | — |
Q2 2021 | May 12, 2021 | $-26.50 | $-3837.59 | -14381.5% | ✗ MISS |
Latest News
Vyome Holdings shares are trading higher after the company announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds.
📈 PositiveBenzinga•Dec 8, 2025, 07:00 PM
Vyome's VT-1953 Announces Phase 2 Efficacy In Malignant Fungating Wounds, Paving Path To Pivotal Trial
📈 PositiveBenzinga•Dec 8, 2025, 01:10 PM
Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders
➖ NeutralBenzinga•Nov 26, 2025, 09:09 PM
Vyome Acquires Oculo, An AI Startup Launched At The Massachusetts Institute Of Technology And Launched A New Business Unit Focused On Using AI To Tackle Inflammation; Deal Terms Were Undisclosed
📈 PositiveBenzinga•Sep 29, 2025, 11:07 AM
Vyome Holdings shares are trading higher after the company announced it presented results from its preclinical studies investigating VT-1908 for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics.
📈 PositiveBenzinga•Sep 17, 2025, 01:03 PM
Market-Moving News for September 17th
➖ NeutralBenzinga•Sep 17, 2025, 11:20 AM•Also: ,
Vyome Unveils Preclinical Data For VT-1908 Eye Drops To Treat Uveitis, A Leading Cause Of Blindness
📈 PositiveBenzinga•Sep 17, 2025, 11:15 AM
Vyome Holdings Announces Interim Data From Phase 2 Study Of VT-1953, Showing VT-1953 Treatment Reduced Malignant Fungating Wound-Associated Malodor
📈 PositiveBenzinga•Sep 4, 2025, 12:35 PM
Vyome Holdings shares are trading higher after the company signed an MoU with Embryyo Technologies to jointly pursue the l AI-enabled medical device market.
📈 PositiveBenzinga•Aug 21, 2025, 05:18 PM
Vyome Holdings Signs MoU With Embryyo To Target Multi-Billion Dollar AI-Enabled Medical Device Market
📈 PositiveBenzinga•Aug 21, 2025, 11:08 AM
Vyome Holdings Enters Amendment No. 1 To Equity Distribution Agreement; Amendment Increases Offering To $12M
📈 PositiveBenzinga•Aug 20, 2025, 09:34 PM
Frequently Asked Questions about HIND
What is HIND's current stock price?
Vyome Holdings, Inc. (HIND) is currently trading at $3.68 per share. The stock has moved -5.08% today.
What is the analyst price target for HIND?
The average analyst price target for HIND is $15.00, based on 1 analyst.
What sector is Vyome Holdings, Inc. in?
Vyome Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HIND's market cap?
Vyome Holdings, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does HIND pay dividends?
No, Vyome Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
CCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
CGEN
Compugen Ltd.
$1.52
Mkt Cap: $0.1B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
NVCT
Nuvectis Pharma, Inc.
$7.78
Mkt Cap: $0.2B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
TNXP
Tonix Pharmaceuticals Holding Corp.
$17.09
Mkt Cap: $0.1B
Explore stocks similar to HIND for comparison